Korean pharmaceutical giant Celltrion on Tuesday pledged to achieve an annual growth rate of 30 percent and a return on equity of at least 7 percent by 2027, as part of its long-term initiative aimed at enhancing corporate value and boosting shareholder returns.

For the next three years, the firm added it would maintain an average shareholder return rate of 40 percent.

This year, Celltrion has set a revenue target of 5 trillion won ($3.45 billion), following record-high revenue of 3.56 trillion won in 2024. The company plans to accelerate growth by strengthening its market position in biosimilars, including Remsima and Truxima, while expanding its young portfolios, which saw its sales figures rise from 26.1 percent to 38.4 percent last year.

The company also expects a significant reduction in the costs of goods sold, which declined from 63 percent in 2023 to approximately 45 percent within a year and aims to reach the 20 percent range by 2027.

To enhance shareholder value, Celltrion will increase dividends, repurchase shares and cancel treasury stocks, targeting a 40 percent shareholder return ratio. The company will issue a record-high dividend of 750 won in cash and 0.05 shares per common share this year.

“With strong sales and portfolio expansion, we have introduced this program to reinforce our corporate vision and commitment to shareholders,” said a Celltrion official. “We aim to become a global top-tier pharmaceutical company while ensuring shared growth with investors.”

By Park Soo-bin (spark@heraldcorp.com)